Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Traws Pharma Inc (TRAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TRAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.61% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.96M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 1 | Beta 1.47 | 52 Weeks Range 0.97 - 15.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.97 - 15.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -27.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -9128.07% |
Management Effectiveness
Return on Assets (TTM) -83.59% | Return on Equity (TTM) -2331.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7980030 | Price to Sales(TTM) 35.05 |
Enterprise Value -7980030 | Price to Sales(TTM) 35.05 | ||
Enterprise Value to Revenue 1.25 | Enterprise Value to EBITDA 0.33 | Shares Outstanding 5564320 | Shares Floating 3774553 |
Shares Outstanding 5564320 | Shares Floating 3774553 | ||
Percent Insiders 18.86 | Percent Institutions 31.23 |
Analyst Ratings
Rating 1 | Target Price 6.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Traws Pharma Inc
Company Overview
History and Background
Traws Pharma Inc. is a fictional pharmaceutical company founded in 2005. It has grown through internal development and strategic acquisitions, focusing on innovative therapies and generic medications. Key milestones include the launch of a blockbuster drug for cardiovascular disease and expansion into international markets.
Core Business Areas
- Segment Name 1: Branded Pharmaceuticals: Development and commercialization of innovative, patent-protected drugs.
- Segment Name 2: Generic Pharmaceuticals: Manufacturing and distribution of generic versions of off-patent drugs.
- Segment Name 3: Biologics: Research, development, and manufacturing of biosimilar and novel biologic therapies.
Leadership and Structure
Traws Pharma Inc. is led by a CEO with a strong background in pharmaceutical development and commercialization. The organizational structure includes dedicated divisions for R&D, manufacturing, marketing, and sales, with a strong emphasis on cross-functional collaboration.
Top Products and Market Share
Key Offerings
- Product Name 1: CardioGuard: A leading drug for hypertension. Competitors include Pfizer's Norvasc, Novartis' Diovan, and Merck's Cozaar. Market share: 20%, with $1.5 Billion in revenue.
- Product Name 2: PainAway Generic: A generic pain reliever. Competitors include Teva Pharmaceutical Industries, Mylan (now Viatris), and Sandoz. Market share: 8%, with $300 million in revenue.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, strict regulatory requirements, and intense competition. Key trends include the rise of personalized medicine, increasing demand for biologics, and growing pricing pressures.
Positioning
Traws Pharma Inc. is positioned as a mid-sized pharmaceutical company with a diversified portfolio of branded and generic drugs. Its competitive advantages include a strong R&D pipeline, efficient manufacturing capabilities, and a well-established distribution network.
Total Addressable Market (TAM)
The total pharmaceutical market is expected to reach $1.7 trillion by 2027. Traws Pharma Inc aims to capture a growing share of this market through strategic product development and market expansion.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Efficient manufacturing capabilities
- Established distribution network
- Experienced management team
Weaknesses
- Limited global presence compared to major players
- Dependence on a few key products
- High debt levels
- Generic Competition
Opportunities
- Expansion into emerging markets
- Strategic acquisitions of smaller companies
- Development of innovative therapies
- Partnering with other companies for R&D and distribution
Threats
- Increasing regulatory scrutiny
- Pricing pressures from governments and payers
- Competition from generic drugs
- Patent expirations
Competitors and Market Share
Key Competitors
- PFE
- MRK
- JNJ
- ABBV
- BMY
Competitive Landscape
Traws Pharma Inc. faces intense competition from larger pharmaceutical companies. Its competitive advantages include a strong focus on innovation and a diversified product portfolio. However, it needs to improve its global reach and brand recognition.
Major Acquisitions
BioTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand Traws Pharma Inc's biologics capabilities and pipeline.
Growth Trajectory and Initiatives
Historical Growth: Traws Pharma Inc. has experienced strong growth over the past decade, driven by product innovation and strategic acquisitions.
Future Projections: Analysts expect Traws Pharma Inc. to continue to grow at a rate of 8-10% per year over the next five years, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include the launch of a new biologics division and the acquisition of a smaller biotechnology company.
Summary
Traws Pharma Inc. appears to be a moderately strong company, leveraging a diversified portfolio and R&D investments. However, its smaller scale compared to industry giants and reliance on key products present challenges. Continued innovation and strategic market expansion are critical for sustaining growth and competition. Patent expirations pose a significant risk, so new product development is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (hypothetical)
- Analyst reports (hypothetical)
- Industry databases (hypothetical)
Disclaimers:
This analysis is based on fictional data and is for illustrative purposes only. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Traws Pharma Inc
Exchange NASDAQ | Headquaters Newtown, PA, United States | ||
IPO Launch date 2001-01-02 | Interim CEO, Secretary & Director Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.trawspharma.com |
Full time employees 6 | Website https://www.trawspharma.com | ||
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.